Show simple item record

dc.contributor.authorFernández de Larrea, C
dc.contributor.authorKyle, R
dc.contributor.authorRosiñol, L
dc.contributor.authorPaiva, B
dc.contributor.authorEngelhardt, M
dc.contributor.authorUsmani, S
dc.contributor.authorCaers, J
dc.contributor.authorGonsalves, W
dc.contributor.authorSchjesvold, F
dc.contributor.authorMerlini, G
dc.contributor.authorLentzch, S
dc.contributor.authorOcio, E
dc.contributor.authorGarderet, L
dc.contributor.authorMoreau, P
dc.contributor.authorSonneveld, P
dc.contributor.authorBadros, A
dc.contributor.authorGahrton, G
dc.contributor.authorGoldschmidt, H
dc.contributor.authorTuchman, S
dc.contributor.authorEinsele, H
dc.contributor.authorDurie, B
dc.contributor.authorWirk, B
dc.contributor.authorMusto, P
dc.contributor.authorHayden, P
dc.contributor.authorKaiser, M
dc.contributor.authorMiguel, JS
dc.contributor.authorBladé, J
dc.contributor.authorRajkumar, SV
dc.contributor.authorMateos, MV
dc.date.accessioned2022-02-18T11:20:19Z
dc.date.available2022-02-18T11:20:19Z
dc.date.issued2021-12-02
dc.identifier.citationBlood cancer journal, 2021, 11 (12), pp. 192 - ?
dc.identifier.issn2044-5385
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5023
dc.identifier.eissn2044-5385
dc.identifier.eissn2044-5385
dc.identifier.doi10.1038/s41408-021-00587-0
dc.identifier.doi10.1038/s41408-021-00587-0
dc.description.abstractPrimary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
dc.formatElectronic
dc.format.extent192 - ?
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePrimary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
dc.typeJournal Article
dcterms.dateAccepted2021-11-15
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41408-021-00587-0
rioxxterms.licenseref.startdate2021-12-02
dc.relation.isPartOfBlood cancer journal
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Myeloma Molecular Therapy
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNot known
icr.researchteamMyeloma Molecular Therapy
dc.contributor.icrauthorKaiser, Martin


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/